Evidence map›Paper›PMID 36788716›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2023

Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare datac.

Naomi B Haas, Yan Song, Jaqueline Willemann Rogerio, Su Zhang, Christopher Carley, JingJing Zhu, Rituparna Bhattacharya, James Signorovitch, Murali Sundaram

Abstract read
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Naomi B HaasUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Yan SongAnalysis Group, Inc., Boston, Massachusetts, USA.
Jaqueline Willemann RogerioMerck & Co., Inc., Rahway, New Jersey, USA.
Su ZhangAnalysis Group, Inc., Boston, Massachusetts, USA.ORCID 0000-0002-2056-8838
Christopher CarleyAnalysis Group, Inc., Boston, Massachusetts, USA.
JingJing ZhuAnalysis Group, Inc., Boston, Massachusetts, USA.
Rituparna BhattacharyaMerck & Co., Inc., Rahway, New Jersey, USA.
James SignorovitchAnalysis Group, Inc., Boston, Massachusetts, USA.
Murali SundaramMerck & Co., Inc., Rahway, New Jersey, USA.

Funding

Merck Sharp and Dohme
6 · The paper itself

Abstract

objectivesThis study aimed to assess whether disease-free survival (DFS) may serve as a predictor for long-term survival among patients with intermediate-high risk or high risk renal cell carcinoma (RCC) post-nephrectomy when overall survival (OS) is unavailable.

methodsThe Surveillance, Epidemiology and End Results-Medicare database (2007-2016) was used to identify patients with non-metastatic intermediate-high risk and high risk RCC post-nephrectomy. Landmark analysis and Kendall's τ were used to evaluate the correlation between DFS and OS. Multivariable regression models were used to quantify the incremental OS post-nephrectomy associated with increased time to recurrence among patients with recurrence, adjusting for baseline covariates.

resultsA total of 643 patients were analyzed; mean age of 75 years; >95% of patients had intermediate-high risk RCC at diagnosis; 269 patients had recurrence post-nephrectomy. For patients with versus without recurrence at the landmark points of 1, 3, and 5 years post-nephrectomy, the 5-year OS were 37.0% versus 70.1%, 42.3% versus 72.8%, and 53.2% versus 78.6%, respectively. The Kendall's τ between DFS and OS post-nephrectomy was 0.70 (95% CI: 0.65, 0.74; p < 0.001). After adjusting for baseline covariates, patients with one additional year of time to recurrence were associated with 0.73 years longer OS post-nephrectomy (95% CI: 0.40, 1.05; p < 0.001).

conclusionThe significant positive association of DFS and OS among patients with intermediate-high risk and high risk RCC post-nephrectomy from this study supports the use of DFS as a potential predictor of OS for these patients when OS data are immature.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAgedDisease-Free SurvivalHumansMedicareNephrectomyRetrospective StudiesUnited Statesdisease-free survivalnephrectomyoverall survivalrecurrencerenal cell carcinoma

Identifiers

PMID36788716
PMCPMC11524080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.